» Articles » PMID: 26650075

High Level of Oxysterols in Neonatal Cholestasis: a Pitfall in Analysis of Biochemical Markers for Niemann-Pick Type C Disease

Overview
Specialties Biochemistry
Pathology
Date 2015 Dec 10
PMID 26650075
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Niemann-Pick disease type C (NPC) is a rare lipid storage disorder characterized by progressive neurological deterioration. Diagnosing NPC is challenging as clinical signs and symptoms are variable and non-specific. Two oxysterols, cholestane-3β,5α,6β-triol (triol) and 7-ketocholesterol (7KC), have been proposed as biomarkers for aiding diagnosis of NPC. This study evaluated the use of triol and 7KC as biomarkers in cholestatic neonates with suspected NPC.

Methods: Plasma triol and 7KC were analysed as dimethylglycine esters using an liquid chromatography - tandem mass spectrometry (LC-MS/MS) assay in selected neonates with severe cholestasis and suspected NPC (n=7), adults with cholestasis (n=15), patients with confirmed NPC (positive controls; n=11 [one child and 10 adults]), healthy subjects (negative controls; n=40 [20 children and 20 adults]), and cholestatic adults (comparative reference; n=15). The LC-MS/MS method was subjected to a number of tests for accuracy and consistency.

Results: Triol and 7KC levels were substantially and significantly increased in NPC positive patients compared with healthy controls (p<0.001). However, positive results (markedly increased levels of both oxysterols) were identified in 6/7 (86%) neonates with cholestasis. Genetic testing confirmed NPC only in one neonate who had increased triol and 7KC, and increased oxysterol levels among neonates with no identified NPC gene mutations were considered likely due to biliary atresia (BA).

Conclusions: While the potential of oxysterols as NPC biomarkers has been well evaluated in older patient populations (without cholestasis), our data suggest that cholestasis might represent a pitfall in oxysterol measurements intended to aid diagnosis of NPC in affected patients.

Citing Articles

Evaluation of the landscape of pharmacodynamic biomarkers in Niemann-Pick Disease Type C (NPC).

Stern S, Crisamore K, Schuck R, Pacanowski M Orphanet J Rare Dis. 2024; 19(1):280.

PMID: 39061081 PMC: 11282650. DOI: 10.1186/s13023-024-03233-7.


Hepatomegaly and Splenomegaly: An Approach to the Diagnosis of Lysosomal Storage Diseases.

Jerves Serrano T, Gold J, Cooper J, Church H, Tylee K, Wu H J Clin Med. 2024; 13(5).

PMID: 38592278 PMC: 10932313. DOI: 10.3390/jcm13051465.


Urinary Metabolic Distinction of Niemann-Pick Class 1 Disease through the Use of Subgroup Discovery.

Carmona C, German-Morales M, Elizondo D, Ruiz-Rodado V, Grootveld M Metabolites. 2023; 13(10).

PMID: 37887404 PMC: 10608721. DOI: 10.3390/metabo13101079.


Elevated oxysterol and N-palmitoyl-O-phosphocholineserine levels in congenital disorders of glycosylation.

Dang Do A, Chang I, Jiang X, Wolfe L, Ng B, Lam C J Inherit Metab Dis. 2023; 46(2):326-334.

PMID: 36719165 PMC: 10023375. DOI: 10.1002/jimd.12595.


The Presence of Vacuolated Kupffer Cells Raises a Clinical Suspicion of Niemann-Pick Disease Type C in Neonatal Cholestasis.

Wang N, Chen L, Lu Y, Xie X, Lin J, Abuduxikuer K Front Genet. 2022; 13:867413.

PMID: 35368683 PMC: 8971202. DOI: 10.3389/fgene.2022.867413.